8-KMaterial AgreementsFinancial EventsOther Events+1

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (May 20, 2026)

Filed May 20, 2026For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) has filed an 8-K to report the entry into a material definitive agreement related to the issuance of $3 billion in aggregate principal amount of senior notes. This issuance, structured across four series with varying maturity dates (2028, 2029, 2031, and 2034) and interest rates ranging from 4.250% to 4.900%, was conducted through a public offering under a previously filed Form S-3 registration statement. The company intends to utilize the net proceeds for general corporate purposes, including potential acquisitions, investments, and strategic transactions, signaling a proactive approach to funding future growth and operational flexibility. The filing also incorporates the underwriting agreement with major financial institutions acting as representatives for the underwriters. Investors should note that while this issuance provides capital, it also increases Gilead's debt obligations and introduces specific covenants and restrictions detailed within the supplemental indenture, such as limitations on secured indebtedness and obligations to repurchase notes upon certain change of control events. The specific redemption prices for the notes are available in their respective forms, which are attached as exhibits to this filing.

Key Highlights

  • 1Gilead Sciences issued $3 billion in aggregate principal amount of senior notes across four tranches: 4.250% due 2028, 4.400% due 2029, 4.600% due 2031, and 4.900% due 2034.
  • 2Proceeds from the note issuance are earmarked for general corporate purposes, including potential acquisitions, investments, and strategic transactions.
  • 3The offering was conducted as a public offering under an effective shelf registration statement on Form S-3.
  • 4The issuance involves an Eleventh Supplemental Indenture to the Company's base indenture dated March 30, 2011.
  • 5The Base Indenture and Eleventh Supplemental Indenture include restrictions on secured indebtedness, sale and leaseback transactions, and asset transfers.
  • 6The company is required to offer to repurchase the notes upon certain change of control events.
  • 7The underwriting agreement was entered into on May 14, 2026, with Barclays Capital Inc., BofA Securities, Inc., and Citigroup Global Markets Inc. acting as representatives for the underwriters.

Frequently Asked Questions

This 8-K filing announces Gilead Sciences, Inc.'s entry into a material definitive agreement for the issuance of $3 billion in senior notes. It details the terms of these notes, the intended use of proceeds, and related indenture agreements.

Gilead Sciences intends to use the net proceeds from the sale of these notes for general corporate purposes. This may include funding for acquisitions, investments, strategic transactions, or other business opportunities.

The notes are divided into four series: $500 million of 4.250% Senior Notes due 2028, $1 billion of 4.400% Senior Notes due 2029, $1 billion of 4.600% Senior Notes due 2031, and $500 million of 4.900% Senior Notes due 2034. Interest is paid semi-annually.

Yes, the indenture agreements contain restrictions on the company's and its subsidiaries' ability to incur secured indebtedness, enter into sale and leaseback transactions, and consolidate or transfer substantially all of its assets. Additionally, the company must offer to repurchase the notes upon certain change of control events.